Theialife plans Phase 3 trials of oral ND10 for progressive pediatric myopia
Theialife said the U.S. Food and Drug Administration has aligned with key elements of the planned Phase 3 development program for ND10, an investigational oral extended-release therapy for progressive pediatric…